Compare Li Auto Inc (LI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Merck & Co., Inc. — how do they compare? Li Auto Inc trades at $12.24 (market cap $12.43B), while Merck & Co., Inc. trades at $125.97 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 24.7× Li Auto Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| LI | MRK | |
|---|---|---|
Market Cap | $12.43B | $307.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $30.84 | $129.52 |
52-Week Low | $11.74 | $77.60 |
Enterprise Value | $1.34B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.21, down 1.45% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31 billion from $144.5 billion in 2024. Recent news includes the launch of new SUV models like the Li L6 in July 2026, aiming to bolster sales in a competitive EV market. Cash flow trends show operational challenges, with negative operating cash flow of $8.61 billion in 2025, though 2026 projections indicate a potential recovery.
Outlook remains cautious due to profitability concerns and intense competition, but analyst consensus suggests upside with a $14.80 price target. Risks include execution hurdles and macroeconomic pressures, yet institutional sentiment leans neutral with 50% hold ratings. Investors should weigh near-term volatility against long-term growth potential in China's EV sector.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
